文献速递中枢神经肿瘤放疗放疗物理与技术

无框架放射外科治疗的局部控制与总生存:单中心经验

Local control and overall survival after frameless radiosurgery: A single center experience.
PubMed 文献 · Clin Transl Radiat Oncol · 2017-11-06

单中心研究纳入48例77个脑转移瘤,采用热塑面罩固定和IGRT的无框架LINAC-SRS,单次剂量20 Gy或18 Gy。69个病灶可评估,粗局部控制率90%,1年局部控制率83%,中位PFS 3.73个月,GTV≤2.0 cm³与更好PFS相关,GTV≤2.5 cm³和颅外稳定与OS相关,耐受性良好。

要点

  • 无框架LINAC-SRS单次20 Gy或18 Gy治疗脑转移瘤,粗局部控制率90%。
  • GTV≤2.0 cm³与更好PFS显著相关,GTV≤2.5 cm³和颅外稳定是OS显著预测因素。
  • 仅2例经组织学诊断放射性坏死,未见其他CTCAE≥3级严重不良反应。

核心结论

  • 采用BrainLAB面罩和ExacTrac X射线6D系统定位的无框架LINAC-SRS耐受性好、安全,粗局部控制率达90%。
  • 无框架SRS的局部控制与文献报道的基于框架的SRS相当,且无需有创头架固定,患者更舒适。

研究设计与样本

  • 单中心研究,2012年2月至2014年1月纳入48例患者共77个脑转移瘤。
  • 处方剂量为单次20 Gy或18 Gy,使用TrueBeam STX Novalis放射外科LINAC,经BrainLAB ExacTrac X射线6D系统和锥形束CT验证定位。

主要发现

  • 77个病灶中69个(90%)有每3个月MRI随访记录,平均随访10.86个月。
  • Kaplan-Meier法估计1年局部控制率为83%,69个病灶中7个(10%)诊断局部失败。
  • 中位无进展生存期(PFS)为3.73个月,主要归因于远处脑复发。
  • GTV≤2.0 cm³较GTV>2.0 cm³与更好PFS显著相关;颅外稳定疾病和GTV≤2.5 cm³是OS的显著预测因素。
  • 观察到2例经手术切除后组织学诊断的放射性坏死,未见其他CTCAE≥3级严重不良反应。

关键数值与推荐

  • 处方剂量为单次20 Gy或18 Gy。
  • GTV≤2.0 cm³与更好PFS显著相关;GTV≤2.5 cm³和颅外稳定疾病是OS显著预测因素。
  • 粗局部控制率为90%(69个可评估病灶中7个局部失败),1年局部控制率83%。

临床怎么用

  • 无框架热塑面罩固定联合IGRT的LINAC-SRS可用于1-3个小型脑转移瘤,无需有创头架。
  • GTV≤2.0 cm³和颅外稳定疾病患者可能从无框架SRS中获得更好PFS或OS。

局限性

  • 单中心、小样本(48例77个病灶),随访时间较短(平均10.86个月)。
  • 仅69个病灶有MRI随访记录,存在随访不完整可能。
  • 为回顾性单臂经验,未与基于框架的SRS进行直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Stereotactic radiosurgery (SRS) has been increasingly advocated for 1-3 small brain metastases. The goal of this study was to evaluate the clinical results in patients with brain metastases treated with LINAC-based SRS using a thermoplastic mask (non-invasive fixation system) and Image-Guided Radiotherapy (IGRT). MATERIAL AND METHODS: In this single-institution study 48 patients with 77 brain metastases were treated between February 2012 and January 2014. The prescribed dose was 20 Gy or 18 Gy as a single fraction. SRS was performed with a True Beam STX Novalis Radiosurgery LINAC (Varian Medical Systems). The verification of positioning was done using the BrainLAB ExacTrac ® X-ray 6D system and cone-beam CT. RESULTS: In 69 of 77 treated brain metastases (90%) the follow-up was documented on MR imaging performed every 3 months. Mean follow-up time was 10.86 months. Estimated 1-year local control was 83%, using the Kaplan-Meier method. In 7/69 brain metastases (10%) local failure (LF) was diagnosed. Median progression free survival (PFS) was 3.73 months, largely due to distant brain relapse. A GTV of ≤2.0 cm3 was significantly associated with a better PFS than a GTV >2.0 cm3. Extracranial stable disease and GTV ≤2.5 cm³ were significant predictors of OS.We observed 2 cases of radiation necrosis diagnosed by histology after surgical resection. No other cases of severe side effects (CTACE ≥ 3) were observed. CONCLUSION: LINAC-based frameless SRS with the BrainLAB Mask using the BrainLAB ExacTrac ® X-ray 6D system for patient positioning is well tolerated, safe and leads to favorable crude local control of 90%. In our experience, local control after frameless (ringless) SRS is as good as ring-based SRS reported in literature. Without invasive head fixation, radiotherapy is more comfortable for patients.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bilger A, Frenzel F, Oehlke O, et al. Local control and overall survival after frameless radiosurgery: A single center experience. Clin Transl Radiat Oncol. 2017. PMID: 29594230. doi:10.1016/j.ctro.2017.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。